more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$44.11 USD

-0.44 (-0.99%)

Updated May 16, 2024 04:00 PM ET

After-Market: $44.11 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?

by Zacks Equity Research Published on March 06,2017

AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.

BMYNegative Net Change

What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

by Zacks Equity Research Published on March 06,2017

Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

by Zacks Equity Research Published on March 06,2017

Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.

Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4

by Zacks Equity Research Published on March 03,2017

Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.

Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

by Zacks Equity Research Published on March 03,2017

Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?

by Zacks Equity Research Published on March 01,2017

Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.

Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y

by Zacks Equity Research Published on February 28,2017

Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.

Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?

by Zacks Equity Research Published on February 27,2017

Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BMYNegative Net Change

Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

by Arpita Dutt Published on February 24,2017

Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.

Bristol Myers' Future Unsure as Carl Icahn Takes Stake

by Joseph Lu Published on February 22,2017

Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?

Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

by Zacks Equity Research Published on February 22,2017

Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

Can Carl Icahn Save Bristol Myers Squibb?

by Joseph Lu Published on February 21,2017

Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.